The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.
 
I-Chun Chen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo Pharmaceutical; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; MSD
 
Ching-Hung Lin
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer
 
Dwan-Ying Chang
Speakers' Bureau - AstraZeneca; Daiichi Sankyo Pharmaceutical; Novartis; Pfizer; Roche
 
Tom Wei-Wu Chen
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Roche
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai; Roche
 
Wei-li Ma
No Relationships to Disclose
 
Ming-Yang Wang
No Relationships to Disclose
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis